Abstract
Discover how ATCC’s HepatoXcell primary human hepatocytes advance microphysiological systems (MPS) for predictive toxicology and drug development. We show genomic, proteomic, and functional data that demonstrate HepatoXcell’s fidelity to liver biology and integration into MPS platforms. This next-generation model supports long-term viability, metabolic activity, and reproducibility, reinforcing ATCC’s commitment to delivering innovative, human-relevant solutions for complex in vitro systems.
This session is an Exhibitor-Hosted Session. Although not an official part of the SOT Annual Meeting scientific program, its presentation is permitted by the Society.
Download this presentation to explore the integration of primary human hepatocytes in MPS platforms
DownloadPresenter
Carolina Lucchesi, PhD
Principal Scientist, BioNexus, ATCC
Carolina Lucchesi is BioNexus Foundation Principal Scientist leading the Microphysiological Systems program at ATCC. Dr. Lucchesi received her PhD in Cellular and Molecular Biology from the University of Campinas in Brazil and has over 20 years of experience in Tissue Engineering and Organ-on-Chip technology. In her current role, Dr. Lucchesi leads the MPS program bringing new capabilities in the use of advanced 3D models and developing existing and new content to be applied in state-of-art technologies.
Primary human hepatocytes are considered the gold standard for in vitro liver models due to their high predictive value in drug metabolism and toxicity studies. They can provide early insights into how a drug will behave in the human body, potentially reducing the risk of adverse effects in clinical trials. ATCC hepatocytes are meticulously isolated and characterized to ensure the highest quality and performance for your drug development and toxicity testing needs. Try our HepatoXcell™ primary human hepatocytes and media today!
Learn more
